Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Recombinant human MGMT|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
O6-Methylguanine-DNA Methyltransferase (MGMT) is an important DNA repair protein involved in tumor cell resistance to the cytostatic activity of chemotherapeutic alkylating agents. This protein is also effective in protecting normal cells against the genotoxic and carcinogenic effects of DNA alkylation. The alkylating drug resistance is caused by MGMT's ability to remove DNA alkyl groups introduced in the O6 position of guanine. MGMT is expressed in highly variable amounts, depending upon the cell and tissue type, species, and cellular growth characteristics. In addition, MGMT activity varies among groups of tumors and within a particular type of tumor.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung.
35-7000 was used in western blot to show that UBR regulates MGMT homeostasis and DNA repair of alkylated DNA adducts in cells.
|Leng S,Wu G,Collins LB,Thomas CL,Tellez CS,Jauregui AR,Picchi MA,Zhang X,Juri DE,Desai D,Amin SG,Crowell RE,Stidley CA,Liu Y,Swenberg JA,Lin Y,Wathelet MG,Gilliland FD,Belinsky SA||Cancer research (75:3108)||2015|
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
35-7000 was used in western blot to study the role of MGMT in the resistance against temozolomide in glioma stem-like cells.
|Qiu ZK,Shen D,Chen YS,Yang QY,Guo CC,Feng BH,Chen ZP||Chinese journal of cancer (33:115)||2014|
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
35-7000 was used in immunohistochemistry - paraffin section to discuss the use of temozolomide to treat pituitary tumors
|Bengtsson D,Schrøder HD,Andersen M,Maiter D,Berinder K,Feldt Rasmussen U,Rasmussen ÅK,Johannsson G,Hoybye C,van der Lely AJ,Petersson M,Ragnarsson O,Burman P||The Journal of clinical endocrinology and metabolism (100:1689)||2015|
|Human||Not Cited||O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.||Pollack IF,Hamilton RL,Sobol RW,Burnham J,Yates AJ,Holmes EJ,Zhou T,Finlay JL||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (24:3431)||2006|
6-O-methylguanine-DNA methyltransferase; methylated DNA protein cysteine methyltransferase; methylated-DNA--protein-cysteine methyltransferase; methylguanine-DNA methyltransferase; O-6-methylguanine-DNA-alkyltransferase; O6-methylguanine-DNA methyltransferase